This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Heidenreich, R. Articles by Breier, G. Search for Related Content PubMed PubMed Citation Articles by Heidenreich, R. Articles by Breier, G.

Tumor Endothelium-specific Transgene Expression Directed by Vascular Endothelial Growth Factor Receptor-2 (Flk-1) Promoter/Enhancer Sequences^1,2

Max-Planck-Institute for Physiological and Clinical Research, 61231 Bad Nauheim, Germany

The receptor tyrosine kinase Flk-1 plays a pivotal role in the development of the vascular system and in the vascularization of a wide variety of tumors. We have investigated the activity of cis-acting sequences of the murine Flk-1 gene in the tumor endothelium of experimental tumor models in vivo. B16 melanoma, BFS-1 fibrosarcoma, and polyoma middle T-induced mammary adenocarcinoma were grown in transgenic mice that express the LacZ reporter gene under the control of a 939-bp Flk-1 promoter fragment and an enhancer element located in a 2.3-kb fragment of the first intron. In all experimental tumor models examined, strong endothelium-specific reporter gene expression was observed while being absent from most blood vessels in normal adult tissue. The expression patterns of the LacZ reporter gene correlate well between established tumors grown in Flk1-LacZ transgenic mice and tumors grown in Flk-1 +/LacZ knock-in mice that express the LacZ reporter gene from the endogenous Flk-1 locus. The endothelium-specific activity of the Flk-1 promoter/enhancer sequences in three different experimental tumor models demonstrates that the regulatory sequences that mediate the up-regulation of Flk-1 in the tumor endothelium are contained in the Flk-1 promoter/enhancer sequences used, and that these elements function relatively independently of the tumor type. The Flk-1 promoter/enhancer sequences should allow the analysis of the signaling pathways that lead to the up-regulation of Flk-1 in the tumor endothelium and to specifically target therapeutic genes to the endothelium of tumors for antiangiogenic tumor therapy.

This article has been cited by other articles:

				K. Ahlbrecht, J. Schmitz, U. Seay, C. Schwarz, R. Mittnacht-Kraus, A. Gaumann, R. V. Haberberger, S. Herold, G. Breier, F. Grimminger, et al. Spatiotemporal Expression of flk-1 in Pulmonary Epithelial Cells during Lung Development Am. J. Respir. Cell Mol. Biol., August 1, 2008; 39(2): 163 - 170. [Abstract] [Full Text] [PDF]

				M.S. Pinsky, W. Song, Z. Dong, K. Warner, B. Zeitlin, E. Karl, D.E. Hall, and J.E. Nor Activation of iCaspase-9 in Neovessels Inhibits Oral Tumor Progression. J. Dent. Res., May 1, 2006; 85(5): 436 - 441. [Abstract] [Full Text] [PDF]

				H. Zhou, Y. Luo, M. Mizutani, N. Mizutani, R. A. Reisfeld, and R. Xiang T cell-mediated suppression of angiogenesis results in tumor protective immunity Blood, September 15, 2005; 106(6): 2026 - 2032. [Abstract] [Full Text] [PDF]

				G. Elvert, A. Kappel, R. Heidenreich, U. Englmeier, S. Lanz, T. Acker, M. Rauter, K. Plate, M. Sieweke, G. Breier, et al. Cooperative Interaction of Hypoxia-inducible Factor-2alpha (HIF-2alpha ) and Ets-1 in the Transcriptional Activation of Vascular Endothelial Growth Factor Receptor-2 (Flk-1) J. Biol. Chem., February 21, 2003; 278(9): 7520 - 7530. [Abstract] [Full Text] [PDF]

				H. Hirai, M. Ogawa, N. Suzuki, M. Yamamoto, G. Breier, O. Mazda, J. Imanishi, and S.-I. Nishikawa Hemogenic and nonhemogenic endothelium can be distinguished by the activity of fetal liver kinase (Flk)-1 promoter/enhancer during mouse embryogenesis Blood, February 1, 2003; 101(3): 886 - 893. [Abstract] [Full Text] [PDF]

				T. Minami, D. J. Donovan, J. C. Tsai, R. D. Rosenberg, and W. C. Aird Differential regulation of the von Willebrand factor and Flt-1 promoters in the endothelium of hypoxanthine phosphoribosyltransferase-targeted mice Blood, December 1, 2002; 100(12): 4019 - 4025. [Abstract] [Full Text] [PDF]